ARQ197

DRUG3 trials

Sponsors

Kyowa Kirin Co., Ltd., Istituto Oncologico Veneto IRCCS

Conditions

CancerCarcinoma, Small CellLiver Cancer

Phase 1

A Phase 1 Study of ARQ 197 in Patients With Solid Tumors

CompletedNCT00609921

Kyowa Kirin Co., Ltd.Cancer

Start: 2008-01-31Target: 42Updated: 2012-09-07

Phase 2

TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)

TerminatedNCT02608411

Istituto Oncologico Veneto IRCCSCarcinoma, Small Cell

Start: 2016-02-19End: 2017-02-21Updated: 2023-10-13

Phase 3

A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)

CompletedNCT02029157

Kyowa Kirin Co., Ltd.Liver Cancer

Start: 2014-01-31End: 2017-08-31Updated: 2017-10-09

Related Papers

A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma

Cancer Science2020-07-2756 citations

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date.

2016-11-1518 citations